SCHEMBL4155346

SCHEMBL4155346

Cc1cccc(Cl)c1C(=O)N1CCCC1

nearest known ligand 0.75

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.75
NPC1 O15118 1/20 0.75
GLA P06280 1/20 0.75
LMNA P02545 1/20 0.53
HCRTR1 O43613 1/20 0.52
HCRTR2 O43614 1/20 0.52
KMT2A Q03164 3/20 0.51
HTT P42858 1/20 0.50
MEN1 O00255 1/20 0.50
PDE2A O00408 1/20 0.49
SMN1; SMN2 Q16637 2/20 0.48
ALDH1A1 P00352 1/20 0.48
MAPT P10636 1/20 0.48
POLB P06746 1/20 0.47
SPR P35270 1/20 0.47
KDM4E B2RXH2 1/20 0.47
HSD17B10 Q99714 1/20 0.47
MAPK10 P53779 1/20 0.47
PLA2G7 Q13093 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4159647 0.88 LMNA (0.61) HPGDNPC1GLALMNAKMT2A
SCHEMBL21163104 0.86 HPGD (0.62) HPGDNPC1GLALMNAKMT2A
SCHEMBL4163104 0.81 HPGD (0.55) HPGDNPC1GLALMNAKMT2A
SCHEMBL24016897 0.80 HPGD (0.56) HPGDNPC1GLALMNAKMT2A
SCHEMBL6367078 0.80 LMNA (0.53) HPGDNPC1GLALMNAKMT2A
SCHEMBL29576558 0.80 MEN1 (0.51) HPGDNPC1GLALMNAHCRTR1
SCHEMBL23244216 0.80 MEN1 (0.51) HPGDNPC1GLALMNAHCRTR1
SCHEMBL11717909 0.80 HTT (0.56) HPGDNPC1GLALMNAHCRTR1
SCHEMBL17502641 0.80 HPGD (0.69) HPGDNPC1GLALMNAHCRTR1
SCHEMBL5100525 0.79 HTT (0.57) HPGDNPC1GLALMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090105292-A9 Glucocorticoid Receptor Modulator Compounds and Methods LIGAND PHARMACEUTICALS INCORPORATED (US) 2009-04-23 US disclosed
US-20070281959-A1 Glucocorticoid receptor modulator compounds and methods LIGAND PHARMACEUTICALS INCORPORATED (US) 2007-12-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105292-A9 Glucocorticoid Receptor Modulator Compounds and Methods NR3C1, NR3C2, MC2R HPGD 272/4885NPC1 1327/4885GLA 1627/4885
US-20070281959-A1 Glucocorticoid receptor modulator compounds and methods NR3C1, NR3C2, MC2R HPGD 272/4885NPC1 1327/4885GLA 1627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.